Overall survival (OS; blue) and progression-free survival (PFS; gold) of all patients (N = 531) in the S0016 study who were randomly assigned to either the R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-RIT (cyclophosphamide, doxorubicin, vincristine, and prednisone followed by consolidation with iodine-133–tositumomab radioimmunotherapy) arm.